Design Therapeutics, Inc. (DSGN)

In the past six months, Design Therapeutics, Inc. has experienced several events impacting its stock, including a stock price increase of 33.49% over the last three months and 79.90% over the last six months. In June 2025, Design Therapeutics announced the start of Friedreich Ataxia patient dosing ex-U.S. in its RESTORE-FA Phase 1/2 trial. In August 2025, the company highlighted progress across its lead GeneTAC® programs, reported its second-quarter 2025 financial results, and announced its participation in the 2025 Cantor Global Healthcare Conference. In September 2025, Design Therapeutics appointed Justin Gover to its Board of Directors.

As a clinical-stage biopharmaceutical company, Design Therapeutics, Inc. does not experience traditional demand seasonality for its products or services. The demand for its therapeutic candidates is driven by the progression of clinical trials, regulatory approvals, and the medical need for treatments for the specific genetic disorders it targets, rather than seasonal consumer patterns.

Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on researching, developing, and commercializing small molecule therapeutic drugs for genetic diseases in the United States, operating within the Healthcare sector, specifically in the Biotechnology & Medical Research industry. The company uses its GeneTAC® platform to develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansions, including therapies for Friedreich Ataxia, Myotonic Dystrophy Type-1, Fuchs Endothelial Corneal Dystrophy, and Huntington's Disease.

Design Therapeutics, Inc. is headquartered in Carlsbad, California, United States. While its primary operations are based in the U.S., the company has initiated patient dosing for its RESTORE-FA Phase 1/2 trial of DT-216P2 for Friedreich Ataxia patients ex-U.S., indicating an international scope for its clinical development activities.

In the past year, Design Therapeutics' reputation has been shaped by its progress in clinical development and corporate governance. Positive contributions to its reputation include the announcement of the start of patient dosing for its Friedreich Ataxia trial and highlighting advancement in its lead GeneTAC® programs. The appointment of Justin Gover to the Board of Directors also reflects ongoing corporate development. Media coverage has focused on company updates and personnel changes, with 9 events covered in the last year. The company's stock performance, which has seen an increase over the past year, also generally contributes to a positive market perception.

Design Therapeutics is primarily owned by institutional shareholders and insiders, who hold 60.63% and 71.45% of the company, respectively, while retail investors hold 0.00%. As of October 6, 2025, 215 institutional owners and shareholders have filed 13D/G or 13F forms, holding a total of 36,934,029 shares. Simeon George is the largest individual shareholder, owning 21.34% of the company, followed by Arsani William and Stella Xu. Key institutional owners include SR One Capital Fund I Aggregator LP, Cormorant Asset Management LP, Quan Venture Fund II LP, Logos Global Management LP, BlackRock, Inc., Frazier Life Sciences Management LP, Point72 Asset Management, L.P., Vanguard Group Inc., and Driehaus Capital Management Llc.